Physician profile
Charles Niesen
NPI 1710915830
$6,795.20
in general payments reported to CMS, 2019-2025
38 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $497 · 2021: $841 · 2022: $1,194 · 2023: $905 · 2024: $1,236 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,317 · Education: $20.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.55 |
| Education | $20.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,131.72 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Sk Life Science, INC. | $789.21 | 2021-2025 | Xcopri |
| Neurelis, INC. | $782.51 | 2020-2025 | Valtoco |
| Corium, LLC | $508.37 | 2021-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $429.78 | 2022-2024 | Epidiolex, Xywav |
| Acadia Pharmaceuticals INC | $213.31 | 2023-2025 | Daybue |
| Aquestive Therapeutics, INC. | $163.84 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $155.93 | 2020-2025 | Qelbree |
| Greenwich Biosciences, INC. | $152.19 | 2019 | |
| Travere Therapeutics, INC. | $151.46 | 2019-2023 | Cholbam |
| Takeda Pharmaceuticals U.S.A., INC. | $133.33 | 2020-2022 | |
| Immedica Pharma US, INC. | $127.90 | 2023 | |
| Merck Sharp & Dohme LLC | $113.91 | 2019 | |
| Sumitomo Pharma America, INC. | $112.04 | 2023 | Aptiom |
| Lilly USA, LLC | $108.29 | 2021-2023 | Reyvow, Emgality |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $100.56 | 2019 | |
| Adlon Therapeutics L.P. | $63.20 | 2020-2021 | |
| Eisai INC. | $53.10 | 2022 | |
| Livanova USA, INC. | $43.54 | 2020-2022 | |
| Neos Therapeutics, LP | $41.43 | 2019-2020 | |
| Abbvie INC. | $34.08 | 2025 | |
| Xeris Pharmaceuticals, INC. | $33.65 | 2022 | |
| Biomarin Pharmaceutical INC. | $33.56 | 2024 | Brineura |
| Tris Pharma INC | $27.59 | 2025 | Dyanavel Xr |
| Mallinckrodt Hospital Products INC. | $27.41 | 2020 | |
| Intrabio INC | $25.88 | 2025 | Aqneursa |
| Biogen, INC. | $25.16 | 2024 | Spinraza |
| Neuropace, INC. | $24.96 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $24.58 | 2023 | Ajovy |
| Arbor Pharmaceuticals, INC. | $24.22 | 2019 | |
| Sarepta Therapeutics, INC. | $23.34 | 2022 | |
| Argenx US, INC. | $22.60 | 2025 | Vyvgart Hytrulo |
| Biohaven Pharmaceuticals, INC. | $20.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.45 | 2024 | Nuedexta |
| Azurity Pharmaceuticals, INC. | $20.29 | 2024 | Zonisade |
| Collegium Pharmaceutical, INC. | $18.37 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $12.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Niesen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.